Who are Fetzima's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Pristiq, Celexa, Plavix, Racemic Sibutramine, Luvox, Serzone.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/levomilnacipran.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Fetzima — Competitive Intelligence Brief

Fetzima (LEVOMILNACIPRAN) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Serotonin and Norepinephrine Reuptake Inhibitor. Area: Neuroscience.

marketed Serotonin and Norepinephrine Reuptake Inhibitor Sodium-dependent serotonin transporter Neuroscience Small molecule Live · refreshed every 30 min

Target snapshot

Fetzima (LEVOMILNACIPRAN) — AbbVie. Fetzima works by blocking the reabsorption of serotonin and norepinephrine in the brain, allowing more of these neurotransmitters to be available for communication between brain cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Fetzima TARGET	LEVOMILNACIPRAN	AbbVie	marketed	Serotonin and Norepinephrine Reuptake Inhibitor	Sodium-dependent serotonin transporter	2013-01-01
Pristiq	desvenlafaxine	Alembic Pharms Ltd	marketed	Serotonin and Norepinephrine Reuptake Inhibitor	Sodium-dependent serotonin transporter	2008-01-01
Celexa	CITALOPRAM	AbbVie	marketed	Serotonin Reuptake Inhibitor	Sodium-dependent serotonin transporter	1998-01-01
Plavix	clopidogrel	Generic (originally Sanofi/BMS)	marketed	Thienopyridine antiplatelet agent	Cytochrome P450 2B6, P2Y purinoceptor 12, Sodium-dependent serotonin transporter	1997-11-17
Racemic Sibutramine	SIBUTRAMINE		marketed	Norepinephrine, Serotonin, and Dopamine Reuptake Inhibitor Anorectic	Sodium-dependent serotonin transporter	1997-01-01
Luvox	FLUVOXAMINE		marketed	Serotonin Reuptake Inhibitor	Sodium-dependent serotonin transporter	1994-01-01
Serzone	NEFAZODONE	Bristol-Myers Squibb	marketed	Serotonin Reuptake Inhibitor	Sodium-dependent serotonin transporter	1994-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Serotonin and Norepinephrine Reuptake Inhibitor class)

AbbVie · 1 drug in this class
Alembic Pharms Ltd · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Fetzima — Competitive Intelligence Brief. https://druglandscape.com/ci/levomilnacipran. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab